NRG1 and gastric cancer: The incidence of NRG1 abnormalities varied depending on the type of tumor examined (Fig. 1C), with a rate of 1.95% in lung cancer (6/307), 0.89% in gastric cancer(5/560), 1.42% in breast cancer (2/141), 0.75% in colorectal cancer (7/930), 1.00% in cholangiocarcinoma (3/301), 0.81% in pancreatic cancer (1/124), 2.63% in laryngocarcinoma (3/114), 0.83% in esophageal cancer (1/121), and 0.81% in soft tissue tumors (1/123).